AEDP (Kidney Bioregulator)
AEDP (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide bioregulator investigated for tissue-specific effects in renal aging, nephroprotection, and kidney gene expression modulation within the Khavinson bioregulatory peptide framework.
AEDP (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide that shares its amino acid sequence with Cortagen, a bioregulator primarily characterized for its neuroprotective properties. Within the Khavinson bioregulatory peptide paradigm, identical short peptide sequences can exhibit tissue-preferential activity depending on the biological context and target tissue microenvironment.
Overview
The observation that short peptides can exert tissue-preferential effects despite lacking classical receptor specificity is a central tenet of Khavinson's bioregulatory peptide theory. Khavinson (2002) proposed that tetrapeptides interact with specific DNA sequences in gene promoter regions, and that the transcriptional outcome depends on which genes are accessible in a given tissue's chromatin landscape. In renal tissue, the AEDP sequence has been explored for its capacity to modulate genes involved in cellular senescence, oxidative stress response, and extracellular matrix homeostasis — processes central to age-related kidney decline.
Kidney aging involves progressive nephron loss, glomerulosclerosis, tubulointerstitial fibrosis, and declining filtration capacity. The bioregulatory approach posits that short peptides may help restore age-diminished gene expression patterns in renal cells, potentially slowing or partially reversing these degenerative processes at the transcriptional level.
Mechanism of Action
AEDP's proposed mechanism follows the general bioregulatory peptide model described by Khavinson and Anisimov (2003), in which short peptides modulate transcription by interacting with chromatin structure rather than through conventional receptor-ligand binding.
Chromatin-Level Gene Regulation: Short peptides including AEDP have been shown to influence heterochromatin condensation state in aging cells. Khavinson et al. (2004) demonstrated that the AEDP sequence induces chromatin decondensation in lymphocytes from elderly subjects, restoring accessibility to gene regions silenced during aging. In renal tissue, this mechanism could reactivate nephroprotective gene programs suppressed by age-related epigenetic drift.
Oxidative Stress Modulation: Kozina (2007) showed that bioactive tetrapeptides including AEDP reduce lipid peroxidation and modulate antioxidant enzyme activity. Given that oxidative stress is a major driver of renal tubular injury and glomerular damage, this antioxidant-shift activity is relevant to nephroprotection.
Tissue-Preferential Expression: The concept that identical peptide sequences can produce different transcriptional outcomes in different tissues is supported by Anisimov et al. (2004), who demonstrated tissue-specific gene expression profiles following AEDP administration. The kidney's distinct chromatin landscape — with active expression of filtration, transport, and reabsorption genes — provides a different substrate for peptide-chromatin interaction than neural tissue.
Reconstitution Calculator
AEDP (Kidney Bioregulator)
**AEDP** (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide that shares its amino aci
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Peptide Bioregulation and Organ-Specific Aging
Khavinson (2002) laid out the theoretical framework for organ-specific peptide bioregulation, proposing that short peptides derived from or designed for specific organs can normalize age-related declines in protein synthesis and cellular function. This framework underpins the investigation of AEDP as a renal bioregulator distinct from its neural (Cortagen) application.
Short Peptide-DNA Interactions
Khavinson et al. (2009) characterized the molecular basis of short peptide interactions with DNA, demonstrating sequence-specific binding to double-stranded DNA in the minor groove. This work provides a structural rationale for how the same tetrapeptide sequence can modulate different gene sets depending on which promoter regions are chromatically accessible in a given tissue type.
Renal Aging and Bioregulation
Age-related kidney decline involves multiple converging mechanisms including oxidative damage, mitochondrial dysfunction, and progressive fibrosis. Khavinson and Anisimov (2003) reviewed the broader bioregulatory peptide approach to organ-specific aging, noting that short peptides can normalize age-altered protein synthesis in target tissues. The kidney, with its high metabolic activity and oxygen consumption, is particularly vulnerable to oxidative aging processes that bioregulatory peptides may modulate.
Chromatin Remodeling in Aging Tissues
Lezhava et al. (2006) demonstrated that bioregulatory peptides including the AEDP sequence can reactivate heterochromatin regions in senescent cells. This chromatin-level intervention is relevant to renal aging because age-related silencing of nephroprotective genes — including those encoding antioxidant enzymes, growth factors, and matrix metalloproteinases — contributes to progressive kidney dysfunction.
Safety Profile
AEDP shares its safety profile with Cortagen, as they are the same tetrapeptide sequence. Preclinical studies have reported no significant adverse effects at experimental doses. As a short peptide composed of natural amino acids (Ala, Glu, Asp, Pro), AEDP undergoes rapid enzymatic degradation to constituent amino acids. No organ-specific toxicity to kidney tissue has been reported in available literature. Formal toxicology studies meeting international regulatory standards specifically targeting renal endpoints have not been published. The peptide's low molecular weight and natural amino acid composition suggest minimal immunogenicity risk.
Pharmacokinetic Profile
AEDP (Kidney Bioregulator) — Pharmacokinetic Curve
Subcutaneous injection, oralQuick Start
- Route
- Subcutaneous injection, oral
Molecular Structure
- Formula
- C₁₇H₂₇N₅O₈
- Weight
- 430.17 Da
- CAS
- Not established
- PubChem CID
- 18439621
- Exact Mass
- 430.1700 Da
- LogP
- -6.5
- TPSA
- 216 Ų
- H-Bond Donors
- 6
- H-Bond Acceptors
- 10
- Rotatable Bonds
- 11
- Complexity
- 711
Identifiers (SMILES, InChI)
InChI=1S/C17H26N4O9/c1-8(18)14(26)19-9(4-5-12(22)23)15(27)20-10(7-13(24)25)16(28)21-6-2-3-11(21)17(29)30/h8-11H,2-7,18H2,1H3,(H,19,26)(H,20,27)(H,22,23)(H,24,25)(H,29,30)/t8-,9-,10-,11-/m0/s1
PLTRIMAUDDQYRV-NAKRPEOUSA-NResearch Protocols
subcutaneous Injection
Administered via subcutaneous injection.
oral
Administered via oral.
Quality Indicators
What to look for
- Multiple peer-reviewed studies available
Frequently Asked Questions
References (9)
- [1]Khavinson VK Peptides and Ageing Neuro Endocrinol Lett (2002)
- [7]
- [8]Khavinson VK et al Peptides and Aging Int J Mol Sci (2020)
- [2]
- [3]Khavinson VK, Lezhava TA, Malinin VV Effects of short peptides on lymphocyte chromatin in senile subjects Bull Exp Biol Med (2004)
- [4]Anisimov SV, Khavinson VK, Anisimov VN Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray Neuro Endocrinol Lett (2004)
- [5]Lezhava T et al Anti-aging peptide bioregulators induce reactivation of chromatin Georgian Med News (2006)
- [6]
- [9]Khavinson VK et al Peptide Regulation of Gene Expression and Protein Synthesis in Bronchial Epithelium Molecules (2021)
Adrenomedullin
Adrenomedullin (ADM) is a 52-amino acid vasodilatory peptide discovered in 1993 from human pheochromocytoma tissue. It acts through the CRLR/RAMP2 receptor complex to produce potent vasodilation, positive inotropy, and renal protection. MR-proADM serves as a critical sepsis and critical illness biomarker, and adrecizumab (anti-ADM antibody) is under investigation for septic shock.
AF-DKP (Selank Metabolite)
AF-DKP is an active cyclic dipeptide (diketopiperazine) metabolite of Selank with independent GABAergic and anxiolytic pharmacological activity, formed during enzymatic degradation of the parent heptapeptide.